HIV Rapid Test Kits Market Size - Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 - 2034

HIV Rapid Test Kits Market Size

The global HIV rapid test kits market is expected to grow significantly between 2025 and 2034, driven by an increasing global focus on early and affordable HIV diagnosis. WHO estimates that roughly 39.9 million individuals were living with HIV at the end of 2023, including 1.4 million children (0-14 years) and 38.6 million adults (15 years and above). Through its Global HIV Programme, WHO facilitates the effective integration of hepatitis and sexually transmitted infection prevention, testing, and treatment with services that meet sexual, reproductive, and mental health needs— all of which are required for providing acceptable and effective programs.
 

Increased awareness campaigns, government programs encouraging early screening, and enhanced access to healthcare are combining to support the market growth. In most nations, mobile clinics, community-based tests, and self-testing programs have picked up pace, having a major impact on the demand for HIV rapid test kits. The increasing incidence of late HIV diagnosis and co-infections such as tuberculosis further highlights the necessity for user-friendly, rapid testing devices. The inclusion of HIV testing in wider health campaigns, such as maternal health and infectious disease screening programs, serves as another central impetus driving the market. The ease of point-of-care (POC) testing, complemented with strong policy support and technological improvement, is establishing the platform for a dynamic growth path over the forecast period.
 

HIV Rapid Test Kits Market Trends

In 2025, the HIV rapid test kits industry is experiencing significant trends that are transforming the scene. The most prominent of them is the popularity of self-test kits. Demand for privacy, convenience, and instant results has prompted manufacturers to develop extremely accurate, intuitive home-based HIV test kits. Manufacturers are further bolstering digital connectivity capabilities by adding app-guided support and telemedicine consultations to provide an end-to-end ecosystem for consumers from test to treatment.
 

The other leading trend is towards fourth-generation quick HIV tests that can identify both HIV-1/2 antibodies and p24 antigen at the same time. These newer tests lower the "window period" between the acquisition of infection and detection, which increases the probability of earlier diagnosis and optimal timing of treatment initiation.
 

Sustainability is also emerging, as firms highlight eco-friendly test kit materials and biodegradable components to lower footprint. As well, partnerships between diagnostic companies and non-profits are expanding to allow access to test kits in low- and middle-income countries for underprivileged populations. The advent of multiplex rapid tests that simultaneously detect HIV together with other STIs such as syphilis and hepatitis is gaining strong momentum. These combination solutions enhance cost savings and patient convenience, targeting the real-world demand for the detection of total diseases at the point of care.
 

HIV Rapid Test Kits Market Analysis

The Nucleic Acid Amplification Test (NAAT) market is expected to register high growth in 2025-2034 as a result of the increased need for accuracy diagnostics. NAAT being a molecular method still boasts unparalleled sensitivity and specificity, thus it remains the gold standard for HIV early detection, particularly in high-risk populations like pregnant women and immunocompromised patients.
 

Latest advances are also refining NAAT technologies for point-of-care use. Miniaturized NAAT platforms coupled with isothermal amplification strategies now facilitate quicker turnaround time with laboratory-quality precision. This is bringing NAAT-based rapid tests within reach even in decentralized and resource-poor environments.
 

Additionally, the cost-effectiveness of NAAT platforms is enhancing through scaling up manufacturing processes and enhanced public-private partnerships. For example, various governments are subsidizing NAAT-based test kits to enhance national HIV testing strategies. With increasing focus on ending undiagnosed infections to achieve 2030 targets, the NAAT segment will remain a key driver in the HIV rapid test kits market.
 

Where sample type is concerned, the blood sample segment is a leading force during the forecast period. But other sample collection methods like dried blood spots (DBS) and oral fluid testing are catching up fast. DBS presents logistical benefits — stable at room temperature and suitable for remote locations — while oral fluid testing delivers a non-invasive, stigma-reducing experience for patients.
 

Significantly, the Centers for Disease Control and Prevention (CDC) of the U.S. has supported the expanded use of self-collected DBS samples in home-testing models, confirming its utility in national HIV surveillance programs. This versatility in sample types facilitates wider use of rapid test kits across different populations, making testing more inclusive and barrier-free.
 

The market for HIV rapid test kits is expected to grow substantially through 2032 due to the improvement of the healthcare infrastructure, public awareness, and an emphasis on preventative healthcare. Increased collaboration between government, healthcare organizations, and private interests is creating an ecosystem that supports the development and access to HIV testing technology with greater access, accuracy, and efficiency- growth of the whole field.
 

HIV Rapid Test Kits Market Share

Major competitors in the market for HIV rapid test kits are:

• bioMérieux
• Biosynex
• Atomo Diagnostics
• OraSure Technologies
• Chembio Diagnostic Systems
• Sedia Biosciences Corporation
• Biolytical Laboratories
• Abbott
• BioSure
• Hologic
   

The players are securing their places through heavy investments in research, product differentiation, and strategic partnerships. They are also adopting sustainability efforts, minimizing plastic usage, and designing eco-friendly packaging for their rapid test kits to attract socially conscious consumers as well as regulatory agencies.
 

HIV Rapid Test Kits Industry News

Abbott launched its new Panbio™ HIV Self Test in November 2022, which can be purchased over the counter from e-commerce channels in Hong Kong, allowing users to get results anywhere, anytime within 15-20 minutes.
 

In April 2025, Atomo Diagnostics gained a $230,000 order from Thorne Harbour Health to provide its HIV Self Test kits in support of the nationwide roll-out of the CONNECT program of the Australian federal government, providing free HIV self-test kits through vending machines in South Australia and Victoria.